Vanda Pharmaceuticals
Logotype for Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) investor relations material

Vanda Pharmaceuticals Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Vanda Pharmaceuticals Inc
Jefferies Global Healthcare Conference summary19 Nov, 2026

Portfolio and financial outlook

  • Five approved products: Fanapt, BYSANTI, HETLIOZ, PONVORY and NEREUS; four are marketed, with BYSANTI launch expected by year-end.

  • Imsidolimab is under FDA review for GPP, with a Dec. 12 PDUFA date and potential sixth product approval by year-end.

  • Q3 revenue was ~$70M, up 24% YoY and 38% sequentially; operating expenses were ~$93M, down ~18% sequentially; cash was $140M.

  • Expenses are expected to moderate as clinical, launch-infrastructure and supply investments conclude; cash is expected to fund operations through at least end-2027.

BYSANTI and psychiatry growth

  • Revenue goal by 2030 is $1B, including $750M from psychiatry and $250M from other products.

  • Fanapt revenue is expected at $140M-$160M for the year; it is expected to go generic in Nov. 2027, while BYSANTI net price is expected to be about 2x Fanapt’s.

  • BYSANTI launch is expected by year-end, initially using Fanapt’s commercial resources; longer term, promotion is expected to shift toward BYSANTI.

  • BYSANTI MDD Phase III readout is expected in H1 2027; positive data could support an sNDA based on one Phase III study, with a label expansion potentially in 2028.

  • MDD represents an estimated 20M additional potential patients versus ~10M for current indications; DTC promotion could be considered if the label expands.

NEREUS opportunity

  • Launched for motion sickness in May; ~70M U.S. people are affected and more than 10M seek treatment. Promotional campaigns have generated website traffic, opt-ins and prescriptions.

  • Motion-sickness WAC is $255 per pill and cash price is $85; growth is expected to be steady and deliberate as promotional efficiency is refined.

  • In a Phase II Wegovy trial, vomiting occurred in 60% of placebo patients versus ~30% with NEREUS; Phase III confirmed a significant reduction, with greater effects among patients with more severe vomiting.

  • FDA discussions and an sNDA are planned; a GLP-1 vomiting label could be possible as early as 2028. Trial use was 14 days around a Wegovy dose, with potential use at initiation, dose escalation or restart.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Vanda Pharmaceuticals earnings date

Logotype for Vanda Pharmaceuticals Inc
Q4 202610 Feb, 2027
Vanda Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Vanda Pharmaceuticals earnings date

Logotype for Vanda Pharmaceuticals Inc
Q4 202610 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ (tasimelteon) for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone) for the treatment of bipolar disorder. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder and smith-magenis syndrome; Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness; Fanapt oral tablets for the treatment of schizophrenia; Novel fixed dose combination products: anoro progesterone vaginal system/norethindrone acetate tablets in women